 Aptevo Therapeutics Inc. APVO, a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a 4.3 million milestone payment from Saol International Limited Saol. This performance-based milestone has been collected more than one year earlier than anticipated in the original contract between Aptevo and Saol. The 4.3 million milestone payment from Saol provides additional non-dilutive capital for our business as we aim to achieve important near-term milestones in both our clinical and commercial programs in 2019 and 2020, said Jeff Lamothe, Chief Financial Officer for Aptevo. 